NEW YORK, Sept. 21, 2012 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. and Accelrys Software Inc. (NASDAQ: ACCL), a leader in scientific innovation lifecycle management software, have formed an alliance partnership towards the development of Aquavit's PITO-001 and MAV-403 products. The partner agreement was signed on September 12, 2012. Under the terms of the partnership, Aquavit will utilize the scientifically aware Accelrys Enterprise Platform to develop advanced medical software for cutting-edge personalized medicine. "It is an exciting opportunity for both companies. As a leading global provider of enterprise scientific informatics software, Accelrys is the ideal partner to accelerate achievement of Aquavit's vision. Having our products powered by the Accelrys Enterprise Platform will support our market leading science," said Sobin Chang, Aquavit's Chief Executive Officer. "We are pleased to be partnering with Aquavit Pharmaceuticals to help accelerate the development of innovative personalized treatments," said Sanjay Gupta, Vice President of Corporate Development at Accelrys. "The Accelrys Enterprise Platform will advance these initiatives by providing unparalleled capabilities in managing end-to-end scientific workflows to achieve better outcomes." This partnership will be led by Thomas S. Benjamin, Vice President of Technology at Aquavit Pharmaceuticals. Mr. Benjamin's award winning research has appeared in The New York Times and The Wall Street Journal. Mr. Benjamin said, "We aim to break new ground with the first-of-a-kind systems in our product lines. We are thrilled to be integrating the powerful Accelrys Enterprise Platform into the development of our next-generation medical technologies." About Aquavit Pharmaceuticals, Inc.Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices, and personalized health technologies. Aquavit's business approach is enhanced by valuable global alliances. Aquavit is developing an innovative drug delivery system that personalizes pharmaceutical solutions based on individual needs. The company is based in New York City and Seoul. About Accelrys Software, Inc.Accelrys (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market. Accelrys solutions are used by more than 1,300 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com. SOURCE Aquavit Pharmaceuticals, Inc.
Accelrys ACCL was soaring nearly 30% to $12.55, its highest point in nearly ten years, on Thursday after news broke that Dassault Systemes would buy the software company for approximately $750 million. Dassault, a software company based in France that designs programs with the aid of computers, announced that it would purchase the San Diego-based Accelrys for $12.50 a share and would make an all-cash tender offer. Accelrys' board has unanimously approved the merger, according to Dassault's statement.